| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Macaca fascicularis | 54 | 2012 | 542 | 2.290 |
Why?
|
| Soybean Proteins | 9 | 2011 | 101 | 1.690 |
Why?
|
| Diabetes Mellitus, Experimental | 9 | 2011 | 64 | 1.520 |
Why?
|
| Lipoproteins, LDL | 16 | 2009 | 99 | 1.310 |
Why?
|
| Isoflavones | 10 | 2011 | 103 | 1.300 |
Why?
|
| Insulin | 17 | 2011 | 359 | 1.200 |
Why?
|
| Animals | 70 | 2012 | 8199 | 1.170 |
Why?
|
| Body Weight | 14 | 2011 | 323 | 1.140 |
Why?
|
| Estrogen Replacement Therapy | 12 | 2007 | 216 | 1.130 |
Why?
|
| Lipids | 18 | 2011 | 253 | 1.100 |
Why?
|
| Estrogens, Conjugated (USP) | 9 | 2009 | 157 | 1.040 |
Why?
|
| Arteriosclerosis | 12 | 2004 | 147 | 0.990 |
Why?
|
| Blood Glucose | 14 | 2012 | 484 | 0.890 |
Why?
|
| Obesity | 7 | 2011 | 1111 | 0.860 |
Why?
|
| Diabetes Mellitus, Type 2 | 7 | 2012 | 1437 | 0.860 |
Why?
|
| Dietary Proteins | 5 | 2009 | 63 | 0.860 |
Why?
|
| Hypoglycemic Agents | 4 | 2011 | 186 | 0.840 |
Why?
|
| Insulin Resistance | 10 | 2010 | 458 | 0.800 |
Why?
|
| Medroxyprogesterone Acetate | 7 | 2007 | 112 | 0.750 |
Why?
|
| Postmenopause | 7 | 2005 | 424 | 0.700 |
Why?
|
| Soybeans | 3 | 2009 | 42 | 0.700 |
Why?
|
| Arteries | 6 | 2011 | 75 | 0.700 |
Why?
|
| Estrogens | 8 | 2005 | 194 | 0.690 |
Why?
|
| Lipoproteins | 8 | 2010 | 95 | 0.660 |
Why?
|
| Coronary Artery Disease | 8 | 2005 | 427 | 0.630 |
Why?
|
| Monkey Diseases | 6 | 2012 | 27 | 0.630 |
Why?
|
| Body Composition | 6 | 2010 | 327 | 0.620 |
Why?
|
| Disease Models, Animal | 8 | 2012 | 1083 | 0.610 |
Why?
|
| Glucose Tolerance Test | 10 | 2011 | 126 | 0.600 |
Why?
|
| Caseins | 3 | 2011 | 21 | 0.550 |
Why?
|
| Hyperglycemia | 4 | 2011 | 85 | 0.550 |
Why?
|
| Liver | 8 | 2011 | 492 | 0.540 |
Why?
|
| Thiazolidinediones | 2 | 2010 | 46 | 0.520 |
Why?
|
| Ovariectomy | 14 | 2005 | 202 | 0.500 |
Why?
|
| Adiponectin | 4 | 2010 | 94 | 0.490 |
Why?
|
| Female | 47 | 2012 | 19945 | 0.480 |
Why?
|
| Carbohydrates | 3 | 2005 | 10 | 0.470 |
Why?
|
| Carbohydrate Metabolism | 4 | 2001 | 21 | 0.440 |
Why?
|
| Menopause | 5 | 2011 | 109 | 0.430 |
Why?
|
| Norpregnenes | 3 | 2003 | 28 | 0.420 |
Why?
|
| Atherosclerosis | 2 | 2011 | 820 | 0.410 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2011 | 215 | 0.410 |
Why?
|
| Glucose Intolerance | 2 | 2011 | 40 | 0.410 |
Why?
|
| Cholesterol | 10 | 2011 | 262 | 0.400 |
Why?
|
| Hormone Replacement Therapy | 3 | 2004 | 94 | 0.390 |
Why?
|
| Streptozocin | 3 | 2011 | 12 | 0.390 |
Why?
|
| Estrogen Receptor Modulators | 3 | 2008 | 26 | 0.370 |
Why?
|
| Prediabetic State | 2 | 2010 | 76 | 0.360 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2010 | 90 | 0.360 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2011 | 717 | 0.350 |
Why?
|
| Diet, Atherogenic | 8 | 2011 | 74 | 0.340 |
Why?
|
| Superoxides | 1 | 2011 | 24 | 0.330 |
Why?
|
| Epigenesis, Genetic | 1 | 2011 | 109 | 0.330 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2011 | 26 | 0.330 |
Why?
|
| Piperidines | 3 | 2010 | 137 | 0.330 |
Why?
|
| Triazines | 1 | 2010 | 8 | 0.320 |
Why?
|
| Anti-Obesity Agents | 1 | 2010 | 9 | 0.320 |
Why?
|
| Azetidines | 1 | 2010 | 11 | 0.320 |
Why?
|
| Iron | 1 | 2011 | 94 | 0.320 |
Why?
|
| Islets of Langerhans | 3 | 2001 | 73 | 0.320 |
Why?
|
| Coronary Disease | 2 | 2001 | 226 | 0.320 |
Why?
|
| Propionates | 1 | 2010 | 8 | 0.320 |
Why?
|
| Fluid Shifts | 1 | 2010 | 4 | 0.320 |
Why?
|
| Male | 26 | 2012 | 19441 | 0.310 |
Why?
|
| Estrogens, Non-Steroidal | 2 | 2001 | 8 | 0.310 |
Why?
|
| Promoter Regions, Genetic | 2 | 2011 | 203 | 0.310 |
Why?
|
| PPAR gamma | 1 | 2010 | 51 | 0.310 |
Why?
|
| Adipose Tissue | 4 | 2007 | 320 | 0.310 |
Why?
|
| PPAR alpha | 1 | 2010 | 24 | 0.310 |
Why?
|
| Adiposity | 2 | 2010 | 190 | 0.310 |
Why?
|
| Sterol O-Acyltransferase | 1 | 2009 | 12 | 0.310 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2010 | 68 | 0.310 |
Why?
|
| Lactalbumin | 1 | 2009 | 15 | 0.300 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2011 | 1050 | 0.300 |
Why?
|
| Heat-Shock Proteins | 1 | 2008 | 38 | 0.280 |
Why?
|
| Hyperinsulinism | 1 | 2008 | 13 | 0.280 |
Why?
|
| Phytotherapy | 1 | 2008 | 36 | 0.280 |
Why?
|
| Transcription Factors | 2 | 2011 | 183 | 0.270 |
Why?
|
| Caloric Restriction | 2 | 2009 | 92 | 0.270 |
Why?
|
| Plant Extracts | 1 | 2008 | 61 | 0.270 |
Why?
|
| Triglycerides | 8 | 2009 | 235 | 0.260 |
Why?
|
| Muscle, Skeletal | 3 | 2009 | 520 | 0.260 |
Why?
|
| Cardiovascular System | 2 | 2004 | 49 | 0.260 |
Why?
|
| Cholesterol, HDL | 8 | 2011 | 181 | 0.250 |
Why?
|
| Lipid Metabolism | 2 | 2011 | 108 | 0.240 |
Why?
|
| Insulin-Secreting Cells | 3 | 2011 | 49 | 0.240 |
Why?
|
| Signal Transduction | 3 | 2011 | 727 | 0.230 |
Why?
|
| Hormones | 1 | 2005 | 24 | 0.230 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2004 | 40 | 0.230 |
Why?
|
| Diabetes Mellitus | 2 | 2001 | 390 | 0.230 |
Why?
|
| Fructosamine | 5 | 2009 | 12 | 0.220 |
Why?
|
| Estradiol | 5 | 2005 | 139 | 0.220 |
Why?
|
| Pancreas | 3 | 2011 | 107 | 0.220 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2004 | 15 | 0.220 |
Why?
|
| Gonadal Steroid Hormones | 3 | 2011 | 40 | 0.210 |
Why?
|
| Dietary Fats | 3 | 2011 | 99 | 0.210 |
Why?
|
| Progesterone | 3 | 1996 | 78 | 0.210 |
Why?
|
| Hyperlipidemias | 1 | 2004 | 61 | 0.200 |
Why?
|
| Cholesterol Esters | 4 | 1997 | 41 | 0.200 |
Why?
|
| Bone Density | 2 | 2001 | 169 | 0.200 |
Why?
|
| Disease Progression | 5 | 2012 | 591 | 0.200 |
Why?
|
| Progestins | 2 | 2000 | 27 | 0.190 |
Why?
|
| Dietary Supplements | 1 | 2003 | 188 | 0.180 |
Why?
|
| Cardiovascular Diseases | 2 | 2002 | 1158 | 0.180 |
Why?
|
| Aging | 3 | 2004 | 942 | 0.180 |
Why?
|
| Risk Factors | 6 | 2012 | 3934 | 0.180 |
Why?
|
| Body Water | 2 | 2012 | 10 | 0.170 |
Why?
|
| Aorta, Abdominal | 2 | 2000 | 31 | 0.170 |
Why?
|
| Osteoporosis | 1 | 2001 | 51 | 0.170 |
Why?
|
| Dogs | 2 | 2012 | 126 | 0.170 |
Why?
|
| Cholesterol, LDL | 3 | 2000 | 170 | 0.170 |
Why?
|
| Pregnancy | 5 | 2011 | 961 | 0.160 |
Why?
|
| Endpoint Determination | 2 | 2010 | 21 | 0.160 |
Why?
|
| Coronary Vessels | 5 | 2004 | 174 | 0.160 |
Why?
|
| Intestinal Absorption | 1 | 2000 | 21 | 0.160 |
Why?
|
| Trans Fatty Acids | 2 | 2010 | 10 | 0.150 |
Why?
|
| Energy Intake | 4 | 2007 | 122 | 0.140 |
Why?
|
| Estrone | 4 | 2005 | 13 | 0.140 |
Why?
|
| Blood Proteins | 2 | 1996 | 19 | 0.140 |
Why?
|
| Plant Proteins | 1 | 1997 | 14 | 0.130 |
Why?
|
| Age Factors | 3 | 2011 | 1179 | 0.130 |
Why?
|
| Random Allocation | 3 | 2004 | 247 | 0.130 |
Why?
|
| C-Peptide | 3 | 2011 | 31 | 0.130 |
Why?
|
| Weight Loss | 2 | 2010 | 410 | 0.130 |
Why?
|
| Breast Neoplasms | 2 | 2011 | 762 | 0.130 |
Why?
|
| Methyltestosterone | 1 | 1996 | 1 | 0.130 |
Why?
|
| Testosterone Congeners | 1 | 1996 | 1 | 0.130 |
Why?
|
| C-Reactive Protein | 2 | 2010 | 227 | 0.120 |
Why?
|
| Humans | 12 | 2012 | 32282 | 0.120 |
Why?
|
| Skin | 1 | 1998 | 212 | 0.120 |
Why?
|
| Pancreatic Diseases | 1 | 1996 | 21 | 0.120 |
Why?
|
| Amyloidosis | 1 | 1996 | 17 | 0.120 |
Why?
|
| Sex Characteristics | 3 | 2007 | 173 | 0.120 |
Why?
|
| Glycosylation | 5 | 1999 | 15 | 0.120 |
Why?
|
| Horses | 3 | 2001 | 18 | 0.120 |
Why?
|
| Animal Feed | 2 | 2009 | 23 | 0.110 |
Why?
|
| Species Specificity | 2 | 2012 | 98 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2011 | 150 | 0.110 |
Why?
|
| Interleukin-3 | 2 | 2004 | 13 | 0.110 |
Why?
|
| Diphtheria Toxin | 2 | 2004 | 28 | 0.110 |
Why?
|
| Primates | 2 | 2012 | 128 | 0.110 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2004 | 120 | 0.100 |
Why?
|
| Contraceptives, Oral, Combined | 1 | 1993 | 7 | 0.100 |
Why?
|
| Phosphorylation | 2 | 2011 | 250 | 0.100 |
Why?
|
| Herpesviridae Infections | 1 | 2012 | 7 | 0.100 |
Why?
|
| Penile Diseases | 1 | 2012 | 4 | 0.100 |
Why?
|
| Vulvar Diseases | 1 | 2012 | 5 | 0.100 |
Why?
|
| Macaca | 2 | 1993 | 30 | 0.100 |
Why?
|
| Linkage Disequilibrium | 2 | 2011 | 181 | 0.100 |
Why?
|
| Tumor Virus Infections | 1 | 2012 | 21 | 0.090 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 1992 | 1 | 0.090 |
Why?
|
| Endometritis | 1 | 1992 | 6 | 0.090 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2008 | 70 | 0.090 |
Why?
|
| Streptococcal Infections | 1 | 1992 | 23 | 0.090 |
Why?
|
| Base Sequence | 2 | 2009 | 252 | 0.090 |
Why?
|
| Diet | 3 | 2012 | 383 | 0.090 |
Why?
|
| Oxygen Isotopes | 1 | 2012 | 9 | 0.090 |
Why?
|
| Deuterium | 1 | 2012 | 11 | 0.090 |
Why?
|
| Fluorine Radioisotopes | 2 | 2009 | 22 | 0.090 |
Why?
|
| Diabetes, Gestational | 1 | 1992 | 28 | 0.090 |
Why?
|
| Hair | 1 | 2012 | 27 | 0.090 |
Why?
|
| Genes, Homeobox | 1 | 2011 | 5 | 0.090 |
Why?
|
| Progesterone Congeners | 3 | 2002 | 22 | 0.090 |
Why?
|
| Oxidative Stress | 2 | 2011 | 255 | 0.090 |
Why?
|
| Muscles | 1 | 2011 | 69 | 0.090 |
Why?
|
| Haplorhini | 2 | 2008 | 75 | 0.090 |
Why?
|
| Mammary Glands, Animal | 1 | 2011 | 69 | 0.090 |
Why?
|
| Apolipoprotein C-III | 1 | 2011 | 6 | 0.080 |
Why?
|
| Arginine | 1 | 2011 | 23 | 0.080 |
Why?
|
| Hypertriglyceridemia | 1 | 2011 | 8 | 0.080 |
Why?
|
| Catalase | 1 | 2011 | 15 | 0.080 |
Why?
|
| Heat Stress Disorders | 1 | 2011 | 9 | 0.080 |
Why?
|
| Diterpenes | 1 | 2011 | 22 | 0.080 |
Why?
|
| Superoxide Dismutase | 1 | 2011 | 41 | 0.080 |
Why?
|
| Ferritins | 1 | 2011 | 38 | 0.080 |
Why?
|
| Antibodies | 1 | 2011 | 56 | 0.080 |
Why?
|
| Heme Oxygenase-1 | 1 | 2011 | 35 | 0.080 |
Why?
|
| Pregnancy Complications | 2 | 2007 | 109 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2011 | 144 | 0.080 |
Why?
|
| Growth | 1 | 2010 | 7 | 0.080 |
Why?
|
| Growth Disorders | 1 | 2010 | 6 | 0.080 |
Why?
|
| Comorbidity | 1 | 2012 | 565 | 0.080 |
Why?
|
| Endometrial Neoplasms | 2 | 2001 | 49 | 0.080 |
Why?
|
| DNA-Binding Proteins | 1 | 2011 | 149 | 0.080 |
Why?
|
| Leptin | 1 | 2010 | 61 | 0.080 |
Why?
|
| Contraceptives, Oral | 2 | 2002 | 26 | 0.080 |
Why?
|
| Extracellular Space | 1 | 2010 | 28 | 0.080 |
Why?
|
| Extracellular Fluid | 1 | 2010 | 16 | 0.080 |
Why?
|
| Phytoestrogens | 2 | 2001 | 25 | 0.080 |
Why?
|
| Eating | 1 | 2010 | 77 | 0.080 |
Why?
|
| Absorptiometry, Photon | 1 | 2010 | 98 | 0.080 |
Why?
|
| Area Under Curve | 1 | 2010 | 90 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2011 | 471 | 0.080 |
Why?
|
| Plant Preparations | 2 | 2001 | 27 | 0.080 |
Why?
|
| DNA Primers | 1 | 2009 | 84 | 0.080 |
Why?
|
| Genome, Viral | 1 | 2009 | 12 | 0.080 |
Why?
|
| Alphapapillomavirus | 1 | 2009 | 12 | 0.080 |
Why?
|
| Patient Compliance | 2 | 2001 | 205 | 0.070 |
Why?
|
| Feeding Behavior | 1 | 2010 | 154 | 0.070 |
Why?
|
| Tritium | 1 | 2009 | 19 | 0.070 |
Why?
|
| Apoptosis | 1 | 2011 | 375 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 821 | 0.070 |
Why?
|
| Celiac Disease | 1 | 1988 | 4 | 0.070 |
Why?
|
| Duodenum | 1 | 1988 | 21 | 0.070 |
Why?
|
| Jejunum | 1 | 1988 | 8 | 0.070 |
Why?
|
| Receptor, Insulin | 2 | 2009 | 9 | 0.070 |
Why?
|
| Insulin Receptor Substrate Proteins | 2 | 2009 | 11 | 0.070 |
Why?
|
| Tissue Distribution | 1 | 2008 | 64 | 0.070 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 1 | 2008 | 6 | 0.070 |
Why?
|
| Papillomavirus Infections | 1 | 2009 | 70 | 0.070 |
Why?
|
| Seeds | 1 | 2008 | 11 | 0.070 |
Why?
|
| Thyroxine | 1 | 2008 | 16 | 0.070 |
Why?
|
| Genetic Variation | 1 | 2009 | 248 | 0.070 |
Why?
|
| Positron-Emission Tomography | 1 | 2009 | 171 | 0.070 |
Why?
|
| Regression Analysis | 1 | 2008 | 273 | 0.070 |
Why?
|
| Endothelium, Vascular | 2 | 2003 | 155 | 0.070 |
Why?
|
| Premenopause | 1 | 2008 | 53 | 0.070 |
Why?
|
| Prognosis | 1 | 2012 | 1534 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2010 | 897 | 0.070 |
Why?
|
| Body Size | 1 | 2007 | 35 | 0.070 |
Why?
|
| Adipocytes | 1 | 2007 | 69 | 0.060 |
Why?
|
| Carotid Arteries | 2 | 2000 | 109 | 0.060 |
Why?
|
| Weight Gain | 1 | 2007 | 104 | 0.060 |
Why?
|
| Rats | 1 | 2010 | 1895 | 0.060 |
Why?
|
| Disease Susceptibility | 1 | 2006 | 61 | 0.060 |
Why?
|
| Androstenedione | 1 | 2005 | 7 | 0.060 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2005 | 8 | 0.060 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2005 | 30 | 0.060 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 128 | 0.060 |
Why?
|
| Multienzyme Complexes | 1 | 2005 | 19 | 0.060 |
Why?
|
| Osmolar Concentration | 1 | 2004 | 23 | 0.050 |
Why?
|
| Rabbits | 1 | 2005 | 219 | 0.050 |
Why?
|
| Fatty Liver | 1 | 2005 | 70 | 0.050 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2004 | 6 | 0.050 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2004 | 7 | 0.050 |
Why?
|
| Abdomen | 1 | 2004 | 44 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2004 | 54 | 0.050 |
Why?
|
| Muscle Proteins | 1 | 2004 | 63 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2004 | 81 | 0.050 |
Why?
|
| Isoprostanes | 1 | 2003 | 3 | 0.050 |
Why?
|
| Fasting | 1 | 2003 | 88 | 0.050 |
Why?
|
| Tamoxifen | 3 | 1999 | 59 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2005 | 541 | 0.050 |
Why?
|
| Androgen Antagonists | 1 | 2002 | 20 | 0.050 |
Why?
|
| Iliac Artery | 1 | 2002 | 50 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2012 | 545 | 0.050 |
Why?
|
| Medroxyprogesterone | 1 | 2001 | 13 | 0.040 |
Why?
|
| Phylogeny | 2 | 2012 | 67 | 0.040 |
Why?
|
| DNA, Viral | 2 | 2012 | 55 | 0.040 |
Why?
|
| Lactation | 2 | 2011 | 18 | 0.040 |
Why?
|
| Permeability | 1 | 2000 | 11 | 0.040 |
Why?
|
| Lipoproteins, HDL | 1 | 2002 | 250 | 0.040 |
Why?
|
| Bile Acids and Salts | 1 | 2000 | 10 | 0.040 |
Why?
|
| Estrogen Antagonists | 2 | 1997 | 16 | 0.040 |
Why?
|
| Organ Size | 2 | 1997 | 221 | 0.040 |
Why?
|
| Endometrium | 1 | 2000 | 44 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2000 | 101 | 0.040 |
Why?
|
| Apolipoproteins | 1 | 2001 | 194 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2004 | 907 | 0.040 |
Why?
|
| Counseling | 1 | 2000 | 93 | 0.040 |
Why?
|
| Proteoglycans | 1 | 1999 | 34 | 0.040 |
Why?
|
| Fluorobenzenes | 2 | 2009 | 32 | 0.040 |
Why?
|
| Aorta, Thoracic | 1 | 1999 | 81 | 0.040 |
Why?
|
| Middle Aged | 2 | 2005 | 11851 | 0.040 |
Why?
|
| Mice | 3 | 2010 | 2571 | 0.030 |
Why?
|
| Gene Expression Regulation | 2 | 2011 | 478 | 0.030 |
Why?
|
| Milk Proteins | 1 | 1997 | 3 | 0.030 |
Why?
|
| Cognition | 1 | 2001 | 547 | 0.030 |
Why?
|
| Testosterone | 1 | 1997 | 48 | 0.030 |
Why?
|
| Blood Vessels | 1 | 1997 | 57 | 0.030 |
Why?
|
| Lipase | 1 | 1997 | 30 | 0.030 |
Why?
|
| Molecular Weight | 2 | 1999 | 55 | 0.030 |
Why?
|
| Testis | 1 | 1997 | 71 | 0.030 |
Why?
|
| Tunica Intima | 1 | 1997 | 76 | 0.030 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 1997 | 18 | 0.030 |
Why?
|
| Chronic Disease | 1 | 1998 | 413 | 0.030 |
Why?
|
| Equilin | 1 | 1996 | 3 | 0.030 |
Why?
|
| Postoperative Period | 1 | 1996 | 95 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2001 | 1425 | 0.030 |
Why?
|
| Hemoglobins | 1 | 1996 | 45 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 1996 | 141 | 0.030 |
Why?
|
| Time Factors | 2 | 1997 | 2205 | 0.030 |
Why?
|
| Reference Values | 2 | 2009 | 238 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 2 | 2004 | 62 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2001 | 3416 | 0.030 |
Why?
|
| Drug Therapy, Combination | 3 | 2002 | 292 | 0.030 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 1993 | 9 | 0.030 |
Why?
|
| Receptors, LDL | 1 | 1993 | 66 | 0.020 |
Why?
|
| Mauritius | 1 | 2012 | 1 | 0.020 |
Why?
|
| Lymphocryptovirus | 1 | 2012 | 1 | 0.020 |
Why?
|
| Streptococcus pyogenes | 1 | 1992 | 16 | 0.020 |
Why?
|
| Adult | 1 | 2005 | 9259 | 0.020 |
Why?
|
| Food Analysis | 1 | 2012 | 7 | 0.020 |
Why?
|
| Aged | 1 | 2005 | 10263 | 0.020 |
Why?
|
| Cellobiose | 1 | 1991 | 1 | 0.020 |
Why?
|
| Receptors, Steroid | 1 | 2011 | 12 | 0.020 |
Why?
|
| Sexual Maturation | 1 | 2011 | 28 | 0.020 |
Why?
|
| Aorta | 1 | 1992 | 125 | 0.020 |
Why?
|
| Models, Animal | 1 | 2012 | 188 | 0.020 |
Why?
|
| Saint Kitts and Nevis | 1 | 2011 | 4 | 0.020 |
Why?
|
| Limit of Detection | 1 | 2011 | 12 | 0.020 |
Why?
|
| DNA, Intergenic | 1 | 2011 | 10 | 0.020 |
Why?
|
| Body Weights and Measures | 1 | 2011 | 23 | 0.020 |
Why?
|
| Reference Standards | 1 | 2011 | 28 | 0.020 |
Why?
|
| Cell Division | 1 | 2011 | 92 | 0.020 |
Why?
|
| Haplotypes | 1 | 2011 | 213 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2011 | 146 | 0.020 |
Why?
|
| Dyslipidemias | 1 | 2011 | 60 | 0.020 |
Why?
|
| Milk, Human | 1 | 2010 | 16 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 315 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 299 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2011 | 179 | 0.020 |
Why?
|
| Abdominal Fat | 1 | 2010 | 39 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2010 | 136 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2010 | 85 | 0.020 |
Why?
|
| Cervical Intraepithelial Neoplasia | 1 | 2009 | 6 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2011 | 256 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 556 | 0.020 |
Why?
|
| Evolution, Molecular | 1 | 2009 | 41 | 0.020 |
Why?
|
| Parasympatholytics | 1 | 2009 | 5 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2009 | 38 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2009 | 23 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2009 | 359 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2009 | 74 | 0.020 |
Why?
|
| Microvilli | 1 | 1988 | 8 | 0.020 |
Why?
|
| Hyperplasia | 1 | 1988 | 37 | 0.020 |
Why?
|
| Atrophy | 1 | 1988 | 46 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 160 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 757 | 0.020 |
Why?
|
| Genome, Human | 1 | 2009 | 130 | 0.020 |
Why?
|
| RNA | 1 | 2009 | 94 | 0.020 |
Why?
|
| Glucose | 1 | 2009 | 160 | 0.020 |
Why?
|
| Genotype | 1 | 2009 | 702 | 0.020 |
Why?
|
| Radiography | 1 | 2009 | 363 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 792 | 0.020 |
Why?
|
| Apolipoproteins B | 2 | 1997 | 48 | 0.020 |
Why?
|
| Apolipoproteins E | 2 | 1997 | 87 | 0.020 |
Why?
|
| Administration, Oral | 2 | 1997 | 200 | 0.010 |
Why?
|
| Heterozygote | 1 | 2005 | 60 | 0.010 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2004 | 34 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2004 | 99 | 0.010 |
Why?
|
| Receptors, Interleukin-3 | 1 | 2004 | 6 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2004 | 164 | 0.010 |
Why?
|
| Half-Life | 1 | 2004 | 24 | 0.010 |
Why?
|
| Anorexia | 1 | 2004 | 6 | 0.010 |
Why?
|
| Chemokine CCL2 | 1 | 2004 | 48 | 0.010 |
Why?
|
| Fatty Acids | 1 | 2005 | 100 | 0.010 |
Why?
|
| Vasculitis | 1 | 2004 | 26 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2004 | 97 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 2004 | 114 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2005 | 454 | 0.010 |
Why?
|
| Macaca mulatta | 2 | 1996 | 340 | 0.010 |
Why?
|
| Esterification | 1 | 2002 | 4 | 0.010 |
Why?
|
| Endothelin-1 | 1 | 2002 | 21 | 0.010 |
Why?
|
| E-Selectin | 1 | 2002 | 20 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 2002 | 38 | 0.010 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2004 | 211 | 0.010 |
Why?
|
| gamma-Tocopherol | 1 | 1999 | 1 | 0.010 |
Why?
|
| Amidines | 1 | 1999 | 4 | 0.010 |
Why?
|
| alpha-Tocopherol | 1 | 1999 | 3 | 0.010 |
Why?
|
| Alkenes | 1 | 1999 | 4 | 0.010 |
Why?
|
| Kinetics | 1 | 1999 | 250 | 0.010 |
Why?
|
| Lipid Peroxidation | 1 | 1999 | 29 | 0.010 |
Why?
|
| Copper | 1 | 1999 | 11 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 1999 | 651 | 0.010 |
Why?
|
| Drug Antagonism | 1 | 1997 | 2 | 0.010 |
Why?
|
| Genitalia, Female | 1 | 1996 | 10 | 0.010 |
Why?
|
| Vasomotor System | 1 | 1996 | 25 | 0.010 |
Why?
|
| Myocardial Ischemia | 1 | 1996 | 98 | 0.010 |
Why?
|
| Norgestrel | 1 | 1993 | 3 | 0.010 |
Why?
|
| Ethinyl Estradiol | 1 | 1993 | 9 | 0.010 |
Why?
|
| Hexosamines | 1 | 1993 | 2 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 1993 | 499 | 0.010 |
Why?
|